IQVIA (NYSE:IQV) Given New $240.00 Price Target at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its price objective dropped by JPMorgan Chase & Co. from $279.00 to $240.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 14.35% from the stock’s previous close.

Several other analysts also recently issued reports on IQV. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Truist Financial decreased their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Barclays reduced their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Morgan Stanley cut their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Trading Down 0.1 %

IQVIA stock traded down $0.31 during mid-day trading on Tuesday, hitting $209.88. 254,770 shares of the stock were exchanged, compared to its average volume of 1,087,992. The stock has a market capitalization of $38.09 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 2.07 and a beta of 1.51. The firm’s fifty day simple moving average is $233.55 and its two-hundred day simple moving average is $229.64. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 12 month low of $190.20 and a 12 month high of $261.73.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. PGGM Investments lifted its stake in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares in the last quarter. SG Americas Securities LLC boosted its stake in IQVIA by 80.1% during the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock worth $11,579,000 after buying an additional 20,369 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in IQVIA in the 1st quarter valued at $3,365,000. Raymond James & Associates increased its stake in shares of IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after acquiring an additional 5,417 shares during the last quarter. Finally, UniSuper Management Pty Ltd raised its holdings in shares of IQVIA by 253.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after acquiring an additional 4,321 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.